Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuro-Oncology and Autophagy-Targeted Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EVA1B drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EVA1B ECD-Fc Fusion Protein High purity (>95%), Endotoxin Controlled (<1 EU/µg). Sequence Verified. HEK293 expressed for native glycosylation. |
View EVA1B Products |
| Gene Delivery | EVA1B Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for cell-based conformation assays. |
View EVA1B Products |
| Benchmark Ab | Anti-EVA1B Recombinant Antibody Recombinant positive control for assay validation and binding benchmark. |
View EVA1B Products |
| Validator | EVA1B siRNA Set Target-specific knockdown verification in functional cell-based assays. |
View EVA1B Products |
| Related Target A | EVA1A High-homology paralog (FAM176A). Crucial for counter-screening to ensure off-target safety. |
View EVA1A Products |
| Related Target B | ROBO1 Axon guidance receptor. Interacts pathway-wise in neural development and glioblastoma cell migration. |
View ROBO1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Off-Target Cross-Reactivity | Highly purified EVA1A and EVA1B ortholog panel proteins strictly verified by mass spectrometry for precise counter-screening. |
| Conformational Integrity in Cell Assays | Lentivirus-mediated stable cell line construction preserves the native transmembrane structure of EVA1B. |
| Lack of Validated Positive Controls | Sequence-verified clinical-grade benchmark antibodies included in the catalog. |
| False Positive Signals in Binding | Validated siRNA sets included for target knockdown and specificity verification. |
Live EVA1B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of EVA1B (also known as FAM176B) is an emerging frontier in neuro-oncology and programmed cell death pathways. As a regulator of autophagy and apoptosis, EVA1B plays a key role in glioblastoma cell survival and migration. The race for EVA1B therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and small-molecule modulators that can cross the blood-brain barrier. As first-generation therapies reach preclinical validation, the next wave of R&D is targeting selective internalization and combination therapies with standard chemotherapeutics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Biotech Startups, Academic Medical Centers | Glioblastoma, Glioma, Solid Tumors | Internalization Assay (Requires high-purity, natively glycosylated ECD-Fc) |
| Monoclonal Antibodies (mAbs) | Oncology-focused Biopharma | Metastatic Cancers, Neuro-degenerative diseases | Affinity & Epitope Mapping (Requires sequence-verified recombinant proteins) |
| Small Molecule Inhibitors/Agonists | Neuroscience & Autophagy Therapeutics Specialists | Glioblastoma, Ischemic Injury | Target Engagement & Cell-based Autophagy Assays (Requires Lentivirus for stable cell lines) |